Načítá se...
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
Antiangiogenic drugs targeting the VEGF pathway have slowed metastatic disease progression in some patients, leading to progression-free survival (PFS) and overall survival benefits compared with controls. However, the results are more modest than predicted by most preclinical testing and benefits i...
Uloženo v:
| Vydáno v: | Nat Rev Clin Oncol |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2011
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4540336/ https://ncbi.nlm.nih.gov/pubmed/21364524 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nrclinonc.2011.21 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|